Loading clinical trials...

A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND) | Clinical Trials | Clareo Health

COMPLETED

A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND)

The ASCEND Study: A Clinical Evaluation of the UP Drug-Coated Device in Patients With Chronic Rhinosinusitis

NCT03599271•Intersect ENT

Summary

The objective of the ASCEND Study is to assess the safety, performance, and efficacy of the Intersect ENT UP Drug-Coated Device when used in chronic rhinosinusitis (CRS) patients undergoing balloon dilation of frontal sinus ostia (FSO)

Detailed Description

This is a prospective, multicenter study enrolling two consecutive cohorts: PK cohort (N=5): A non-randomized cohort to assess the systemic safety and performance of the UP Drug-Coated Device for in-office bilateral dilation of the FSO (2 inflations in each FSO for a total of 4 inflations per device). Subsequently, the UP Drug-Coated Device may be used to dilate any sphenoid or maxillary sinuses. Randomized cohort (N=70): A randomized, intra-patient controlled, double-blind cohort of 70 subjects to assess the safety and efficacy of the UP Drug-Coated Device used for in-office dilation of the FSO. The FSO randomized to the treatment (Treatment) will undergo dilation using the UP Drug-Coated Device (2 inflations per device) while the contralateral FSO (Control) will be dilated with a UP Control Device (2 inflations per device).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Confirmed diagnosis of CRS per the 2016, "International Consensus Statement on Allergy and Rhinology" definition.
•2. Bilateral disease in the frontal sinuses (Lund-Mackay score ≥ 1 on each side) on CT scan within 30 days prior to enrollment in the PK cohort and prior to randomization in the randomized cohort.
•3. Patient has bilateral obstruction of the frontal recess/FSO due to scarring and/or polypoid edema confirmed on endoscopy (patency grade of 0 or 1 for each FSO).
•4. Balloon dilation of the FSO judged to be feasible and medically appropriate.
•5. Patient has had prior ESS (\> 30 days with a healed mucosa) including bilateral ethmoidectomy (anterior or total) and uncinectomy for better visualization of the FSO.
•6. Balloon dilation of the FSO with a 6 mm balloon is judged to be feasible (use light-assisted or image-guided instrument such as a frontal sinus seeker tip to confirm access of each FSO) and medically appropriate.

Exclusion Criteria

•1. Expanded amount of ethmoid polyposis (grade \> 2 PK cohort, grade ≥ 2 randomized cohort).
•2. Complications from prior ESS or balloon dilation procedure (e.g., cerebrospinal fluid leak or injury to the skull base).
•3. History of aspirin exacerbated respiratory disease (AERD).
•4. Current smokers.
•5. History of allergy or intolerance to mometasone furoate.
•6. Oral-steroid dependent condition.
•7. Evidence of acute rhinosinusitis, invasive fungal sinusitis or another disease or condition expected to compromise survival or ability to complete assessments during the 30-day follow-up period in the PK cohort and druing the 60-day follow-up period in the randomized cohort.
•8. Use of parenteral and injected steroids (e.g., Kenalog) 30 days prior to the baseline procedure.
•9. Use of oral steroids, budesonide or other sinus steroid irrigations/rinses or drops, nebulized steroids administered nasally 14 days prior to screening in the PK cohort and prior to baseline in the randomized cohort.
•10. Glaucoma or posterior subcapsular cataract.

Locations (1)

Centers for Advanced ENT Care

Baltimore, Maryland, United States

Key Dates

Start Date

June 12, 2018

Primary Completion Date

December 15, 2019

Completion Date

December 9, 2020

Last Updated

May 26, 2021

Enrollment

ACTUAL participants

Conditions

Chronic Rhinosinusitis (Diagnosis)

Interventions

Drug-Coated Device

DEVICE

Control Device

DEVICE

Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis

NCT05427695

Chronic Rhinosinusitis (Diagnosis)

View study

ACTIVE_NOT_RECRUITING

The Sinonasal Microbiome

NCT06822725

Sinonasal DisorderChronic Rhinosinusitis (Diagnosis)

View study

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2

Functional Endoscopic Sinus Surgery Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 26, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND)

Inclusion Criteria

Exclusion Criteria

Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis

The Sinonasal Microbiome

Functional Endoscopic Sinus Surgery Study

Post-operative Pain Control With Acetaminophen and Ibuprofen After Functional Endoscopic Sinus Surgery

Aggravated Airway Inflammation: Research on Genomics and Optimal Medical Care (AirGOs-medical)

Nasal Microbiota Transfer Therapy in Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)